LYSA presentations in June 2021 international congresses

• CNS Relapse in DLBCL patients below 60 years treated with R-ACVBP, R-CHOEP, or R-CHOP: A joint analysis of LYSA and GLA/DSHNHL Catherine Thieblemont

• Atezolizumab + Obinutuzumab + Venetoclax in patients with relapsed or refractory indolent non-Hodgkin’s lymphoma in (R/R INHL): primary analysis of a Phase 2 trial from LYSA  Charles Herbaux

• Atezolizumab + Obniutuzumab + Venetoclax in patients with relapsed or refractory indolent non-Hodgkin’s lymphoma in (R/R INHL): primary analysis of a Phase 2 trial from LYSA

Oral communication by Charles Herbaux

• First results of DLBCL patients treated with CAR-T cells and enrolled in DESCAR-T registry, The French real-life database for CAR-T cells in hematologic malignancies.

Oral communication by Steven Le Gouill

• Prospective Evaluation of Lymphoma response to immunomodulatory therapy criteria (lyric) in GATA trial from the LYSA Group – (GATA TEP)

Poster by Yassine Al Tabaa

• Early Positron Emission Tomography Response-Adapted Treatment in Localized Diffuse Large B-Cell Lymphoma (aaIPI=0): Results of the Phase 3 LYSA LNH-09-1B Trial

Oral communication 005 in plenary session by Serge Bologna

• Defining ultra-high-risk DLBCL patients prior to initial treatment based on an integrative host and disease prognostic score (from REMARC study)

Oral communication 017 in general session 2: Catherine Thieblemont

• Monomorphic Epitheliotropic Intestinal T-cell Lymphoma (MEITL): clinico-pathological analysis of a multicenter European cohort.

Oral communication 044 in session 6: Doriane Cavalieri

• Outcomes after first-line immunochemotherapy for primary mediastinal B cell lymphoma patients: a LYSA study.

Oral communication 050 in session 7: Vincent Camus

• First results of DLBCL patients treated with CAR-T cells and enrolled in DESCAR-T registry, a French real-life database for CAR-T cells in hematologic malignancies.

Oral communication 084 in session 13: Steven Le Gouill

• Atezolizumab + Obinutuzumab + Venetoclax in patients with relapsed or refractory Marginal Zone Lymphoma: primary analysis of a phase 2 trial from LYSA

E-poster & Abstract Book Nr. 145: Charles Herbaux

• Atezolizumab + Obinutuzumab + Venetoclax in patients with relapsed or refractory Follicular Lymphoma: primary analysis of a phase 2 trial from LYSA

E-poster & Abstract Book Nr. 110: Guillaume Cartron

• Circulating tumor DNA load and total metabolic tumor volume in Diffuse Large B Cell Lymphoma (DLBCL) patients treated by R-CHOP – From REMARC, a LYSA study

E-poster by Catherine Thieblemont

• High adipose tissue density is a negative prognostic factor in DLBCL patients treated by R-CHOP, independent from TMTV and PS-From the REMARC study

E-poster by Catherine Thieblemont

• Selinexor in Combination with R-GDP for Patients with Relapsed/ Refractory B-Cell Lymphoma: Preliminary results of the SELINDA phase Ib LYSA study (EUDRACT Number: 2015-005612-15)

E-poster by Marie Maerevoet

• Long-term outcomes of elderly patients treated with frontiline R-CHOP: update of the LNH03-6B trial
  

E-poster by Vincent Camus

• Impact of DUSP22 rearrangement on the prognosis of systemic ALK-negative anaplastic large cell lymphoma : a LYSA and TENOMIC study

E-poster by David Sibon

• 199 – Brentuximab vedotin as consolidation treatment in patients with stage I/II classical Hodgkin’s lymphoma and a positive FDG-PET after 2 cycles of ABVD : a LYSA phase 2 study

E-poster by Thomas Gastinne

• Prospective evaluation of lymphoma response to immunomodulatory therapy criteria (lyric) in GATA trial from the LYSA group

E-poster & Abstract Book n°245 by Yassine Al Tabaa

• Gender disparities in quality of life of French patients one year after the diagnosis of Lymphoma, a LYSA study

E-poster & Abstract Book n°280 by Caroline Besson

• A widespread T-cell exhaustion pattern is frequent in the tumor microenvironment of relapsed/refractory B-cell Lymphoma patients and could be circumvented by PDL1 blockade.

Abstract book by Camille Laurent